Mersana Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference

CAMBRIDGE, Mass.--()--Mersana Therapeutics, Inc., today announced that Anna Protopapas, President and Chief Executive Officer, will present a company overview at the Cowen and Company 37th Annual Health Care Conference at the Boston Marriott Copley Place in Boston on Monday, March 6, 2017, from 3:00 -3:25pm EST.

About Mersana Therapeutics

Mersana Therapeutics is a biotechnology company with highly differentiated and proprietary immunoconjugate platforms that allow for significantly higher drug loads, providing greater efficacy while simultaneously increasing tolerability. As a result, our platforms create expanded opportunities to deliver meaningful clinical benefit to patients. Our lead program, XMT1522, is in Phase I clinical trials. Our second program, XMT1536, will be entering clinical trials in the latter part of 2017. In addition, our partners are advancing their pipeline of immunoconjugates using our platforms.

Contacts

For Mersana Therapeutics, Inc.
Media
Paul Kidwell, 617-680-1088
paulkidwell@comcast.net
or
Investors
Stern Investor Relations, Inc.
Christina Tartaglia, 212-362-1200
Christina@sternir.com

Recent Stories

RSS feed for Mersana Therapeutics, Inc.